A Phase 2 interventional study of AFM13 and AB-101 in Relapsed or Refractory Hodgkin Lymphoma and Peripheral T Cell Lymphoma, sponsored by Affimed GmbH. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Affimed GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.
Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 503rd largest by enrollment of the 818 interventional ones that give a count, is one of 12 that started in 2023, is one of 346 in phase 2, and was the 924th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
M.D. Anderson Cancer Center · Sites in United States
Ages 2–21
Michael Spinner, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
970 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 389 · Phase 2 460 · Phase 3 57 · Phase 4 1
First in 1988; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 35 across the 818 interventional studies, 111 across the 80 observational. Of the 779 that completed or were terminated, 326 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
137 of 970 have an industry lead sponsor. The 10 most frequent:
Affimed GmbH is the lead sponsor of 9 studies on the registry; none are open to participants now.
Affimed GmbH has 3 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
49 of the studies in Hodgkin Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01483664Memorial Sloan Kettering Cancer CenterCommunication Skills Intervention to Promote Transition Into Survivorship | 2026-11 |
| NCT03681561Veronika BachanovaNivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | 2026-11 |
| NCT06923397Dana-Farber Cancer InstituteInterrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | 2026-11-28 |
| NCT05723055University of UtahEvaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2026-12 |
| NCT06150664Compass TherapeuticsA Phase 1 of CTX-8371 in Patients With Advanced Malignancies | 2026-12 |
Add all 49 to your calendar (.ics) → With an account.
Among the 970 studies in Hodgkin Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
The study will start with a safety run-in exploring AFM13/AB-101 combination treatment in subjects with classical HL. Two dose levels of AFM13 and AB-101, respectively, will be tested in 4 cohorts. Cohort 1 and 2 will enroll in parallel. Enrolment into Cohort 3 and 4 will start only if the combination treatment has been well tolerated.
Following the safety run-in observation period, a thorough risk-benefit analysis will be performed to determine 2 of the 4 cohorts/dose levels that will be further evaluated in the main part of the study which will also include subjects with classical HL and will follow a Simon two-stage design.
An additional exploratory cohort (Cohort 5) will enroll subjects with select CD30-positive PTCL subtypes after completion of the safety run-in.
All subjects will be treated with AFM13/AB-101 for a maximum of 3 cycles (cycle length is 48-days).
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
This study's enrollment of 25 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Affimed GmbH is the lead sponsor of 9 studies on the registry; none are open to participants now.
Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 safety run-in cohorts: * Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15) * Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15) * Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15) * Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)
Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2
Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level A (selected from cohort 1-4 of Safety run-in)
Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2
Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level B (selected from cohort 1-4 of Safety run-in)
Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2
AFM13 + AB-101 on select CD30-positive PTCL subtypes (Dose Level A or B)
Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2
anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
NK cell therapy, intravenous infusion
Lymphodepleting chemotherapy, intravenous infusion
Lymphodepleting chemotherapy, intravenous infusion
Immune cytokine, subcutaneously
Objective Response Rate (ORR) by Independent Radiology Committee
Best ORR (complete response (CR) + partial response \[PR\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification. A participant will be assumed as a responder if he/she achieves complete or partial response at any postbaseline visit.
Time frame: Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.
Duration of Response by Independent Radiology Committee
Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed by Independent Radiology Committee.
Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Complete Response Rate (CRR) by Independent Radiology Committee
Complete Response Rate based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.
Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
ORR by Investigator Based on PET-CT as Assessed by the Lugano Classification
ORR (CR + PR) by Investigator based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification
Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Duration of Response by Investigator
Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed locally by the Investigator.
Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Incidence of Subjects Receiving Subsequent Transplant
The number of subjects receiving subsequent transplant will be assessed and summarized by percentage rates
Time frame: Throughout study completion (up to 20 months)
Frequency of Subjects With Study Drug Related TEAEs
The number of subjects with study-drug related (AFM13 or AB-101) treatment-emergent adverse events (TEAEs)
Time frame: From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)
Frequency of Subjects With Serious Treatment Emergent Adverse Events
The number of subjects who had serious treatment emergent adverse events.
Time frame: From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)
Frequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM13
The number of subjects developing anti-drug antibodies (ADAs) against AFM13
Time frame: During treatment cycles (up to 6 months)
Progression-free Survival (PFS) by Independent Radiology Committee
Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until progressive disease (PD). Subjects who started a new anti-lymphoma therapy prior to a documented progressive disease were censored at the last disease assessment prior to initiation of new anti-lymphoma therapy. Subjects who discontinued the study before the first assessment of progressive disease or death were censored at their last disease assessment.
Time frame: From the first treatment received until the first progression disease assessed by IRC or death.
Overall Survival
Overall Survival (OS) was defined as (date of death - date of first dose)/30.4375. Patients alive at the end of study will be censored on the last date of observation.
Time frame: From the first treatment received until the death.
| Milestone | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Started | 6 | 7 | 6 | 6 |
| Completed | 1 | 3 | 6 | 3 |
| Not completed | 5 | 4 | 0 | 3 |
Best ORR (complete response (CR) + partial response \[PR\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification. A participant will be assumed as a responder if he/she achieves complete or partial response at any postbaseline visit.
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Objective Response Rate (ORR) by Independent Radiology Committee | 5 | 5 | 6 | 5 |
Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed by Independent Radiology Committee.
| months | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Duration of Response by Independent Radiology Committee | 4.90 (2.20 to NA) | NA (NA to NA) | NA (NA to NA) | 6.97 (2.30 to NA) |
Complete Response Rate based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Complete Response Rate (CRR) by Independent Radiology Committee | 4 | 3 | 4 | 3 |
ORR (CR + PR) by Investigator based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| ORR by Investigator Based on PET-CT as Assessed by the Lugano Classification | 4 | 5 | 6 | 6 |
Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed locally by the Investigator.
| months | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Duration of Response by Investigator | 3.86 (2.20 to NA) | 6.28 (2.10 to NA) | NA (NA to NA) | 4.65 (2.30 to NA) |
The number of subjects receiving subsequent transplant will be assessed and summarized by percentage rates
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Incidence of Subjects Receiving Subsequent Transplant | 1 | 2 | 0 | 1 |
The number of subjects with study-drug related (AFM13 or AB-101) treatment-emergent adverse events (TEAEs)
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Frequency of Subjects With Study Drug Related TEAEs | 5 | 4 | 5 | 5 |
The number of subjects who had serious treatment emergent adverse events.
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Frequency of Subjects With Serious Treatment Emergent Adverse Events | 2 | 5 | 4 | 5 |
The number of subjects developing anti-drug antibodies (ADAs) against AFM13
| Participants | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Frequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM13 | 2 | 1 | 2 | 1 |
Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until progressive disease (PD). Subjects who started a new anti-lymphoma therapy prior to a documented progressive disease were censored at the last disease assessment prior to initiation of new anti-lymphoma therapy. Subjects who discontinued the study before the first assessment of progressive disease or death were censored at their last disease assessment.
| months | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Progression-free Survival (PFS) by Independent Radiology Committee | 4.17 (1.45 to NA) | 7.66 (1.28 to NA) | NA (NA to NA) | 8.28 (1.35 to NA) |
Overall Survival (OS) was defined as (date of death - date of first dose)/30.4375. Patients alive at the end of study will be censored on the last date of observation.
| months | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Overall Survival | NA (NA to NA) | 12.25 (3.48 to NA) | 9.72 (NA to NA) | NA (NA to NA) |
Collected over From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety run-in Cohort 1 | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Safety run-in Cohort 2 | 4/7 (57.1%) | 5/7 (71.4%) | 7/7 (100%) |
| Safety run-in Cohort 3 | 1/6 (16.7%) | 4/6 (66.7%) | 6/6 (100%) |
| Safety run-in Cohort 4 | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 1/6 | 1/7 | 0/6 | 2/6 |
| PneumoniaInfections and infestations | 1/6 | 0/7 | 0/6 | 1/6 |
| Cytomegalovirus OesophagitisInfections and infestations | 1/6 | 0/7 | 0/6 | 0/6 |
| Cytomegalovirus ViraemiaInfections and infestations | 1/6 | 0/7 | 0/6 | 0/6 |
| UrosepsisInfections and infestations | 0/6 | 0/7 | 1/6 | 0/6 |
| Cytokine Release SyndromeImmune system disorders | 1/6 | 1/7 | 1/6 | 1/6 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/7 | 0/6 | 1/6 |
| PyrexiaGeneral disorders | 0/6 | 1/7 | 0/6 | 1/6 |
| MalaiseGeneral disorders | 1/6 | 0/7 | 0/6 | 0/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/6 | 0/7 | 1/6 | 0/6 |
| Event | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/6 | 6/7 | 4/6 | 4/6 |
| ConstipationGastrointestinal disorders | 4/6 | 5/7 | 3/6 | 2/6 |
| VomitingGastrointestinal disorders | 4/6 | 5/7 | 2/6 | 1/6 |
| FatigueGeneral disorders | 4/6 | 5/7 | 4/6 | 1/6 |
| PyrexiaGastrointestinal disorders | 4/6 | 5/7 | 0/6 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 4/6 | 1/7 | 3/6 | 0/6 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/6 | 4/7 | 4/6 | 2/6 |
| HeadacheNervous system disorders | 3/6 | 3/7 | 4/6 | 1/6 |
| HypokalaemiaMetabolism and nutrition disorders | 4/6 | 2/7 | 1/6 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 4/6 | 3/7 | 1/6 | 2/6 |
Safety Analysis Set
| Age, Continuous(years) | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 50.5 ± 20.68 | 43.6 ± 19.21 | 54.7 ± 14.61 | 46.0 ± 19.8 | 48.5 ± 18.07 |
| Sex: Female, Male(Participants) | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 3 | 6 | 4 | 4 | 17 |
| Male | 3 | 1 | 2 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 6 | 7 | 5 | 5 | 23 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Safety run-in Cohort 1 | Safety run-in Cohort 2 | Safety run-in Cohort 3 | Safety run-in Cohort 4 | Total |
|---|---|---|---|---|---|
| United States | 6 | 7 | 6 | 6 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2023 to primary completion in Nov 2024, 12 months.
Results were first posted in Aug 2025, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AFM13 · AB-101
Affimed GmbH